慢性淋巴细胞性白血病脾脏放疗(SI)始于放疗应用的早期,但有争论。最近几年,几个权威报告了SI部分有效率可高达60%。基于血液学和免疫学经验,SI的可行性和血液学的选择性为CLL病人提供了一个可选择的余地,使这种疗法得以复兴。SI的潜在优势是恶性淋巴细胞的破坏最终使淋巴细胞数量降低,骨髓浸润减轻和肿大的脾脏缩小,T淋巴抑制细胞破坏(存在于脾脏,引起贫血和血小板减少)。 Chronic lymphocytic leukemia Spleen radiotherapy (SI) started early in the use of radiotherapy, but is debatable. In recent years, several authorities have reported that the SI part can be as efficient as 60%. Based on the experience of hematology and immunology, the viability and hematological selectivity of SI provide an alternative for CLL patients to revive this therapy. A potential advantage of SI is that the destruction of malignant lymphocytes ultimately results in a decrease in the number of lymphocytes, diminished bone marrow infiltrates and an enlarged spleen that inhibits cell destruction (present in the spleen, causing anemia and thrombocytopenia).